Histogenics Corporation
830 Winter Street
3rd Floor
Waltham
Massachusetts
02451
United States
Tel: 781-547-7900
Fax: 781-547-4452
Website: http://www.histogenics.com/
Email: info@histogenics.com
75 articles about Histogenics Corporation
-
Ocugen Announces Completion of its Merger with Histogenics to Create Nasdaq-Listed Clinical-Stage Company Developing Novel Ocular Gene Therapies and Biotherapeutics
9/30/2019
Ocugen, Inc., announced the completion of its merger with Histogenics Corporation, and the change of the combined company’s name to “Ocugen, Inc.” Ocugen is expected to begin trading on The Nasdaq Capital Market under the ticker symbol “OCGN.” The executive team of Ocugen has become the executive team of the combined company, led by Shankar Musunuri, Ph.D., M.B.A., as Chairman, Chief Executive Officer and Co-Founder.
-
As the largest center for biotech startups in the U.S., the Boston/Cambridge, Massachusetts area often acts as a marker for the entire industry. Here’s a look at the Massachusetts M&A deals so far.
-
Bone-on-bone knee pain from osteoarthritis can be agonizing and often results in surgery. But for some patients, there is another therapy option gaining ground – engineered cartilage implants.
-
Histogenics Corporation Announces Second Quarter 2018 Financial and Operating Results
8/9/2018
Top-line Superiority Data from NeoCart ® Phase 3 Clinical Trial on Track for Third Quarter of 2018
-
Histogenics Corporation Appoints E. Lynne Kelley, M.D., FACS As Chief Medical OfficerExperienced Surgeon and Life Sciences Executive to Lead Medical Affairs, Clinical and Regulatory Operations in Preparation for Potential Commercial Launch of NeoCart®
7/31/2018
WALTHAM, Mass., July 31, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies (RCTs) that may offer rapid-onset pain relief and restored function, today announced the appointment of E. Lynne Kelley, M.D., FACS as its Chief Medical Officer. Dr. Kelley brings more than 20 years of executive management and surgical experience in medical affairs, clinical operations, regulatory affairs and product development to His
-
Histogenics Corporation to Report Second Quarter 2018 Financial Results on August 9, 2018
7/26/2018
Histogenics Corporation announced it will report its second quarter 2018 financial results on August 9, 2018, before the U.S. financial markets open.
-
Artificial body parts have been around for some time. Patients have access to artificial limbs, hearts, eyes, skin and more thanks to the innovation of biomedical engineers. As technology improves, so do the advancements in these man-made devices.
-
Histogenics Corporation Announces Closing of Underwritten Registered Direct Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
1/26/2018
The total net proceeds of the offering are approximately $5.9 million after deducting the underwriting discounts and commissions payable by Histogenics.
-
Histogenics Corporation Announces Pricing of Underwritten Registered Direct Offering of 2,340,430 Shares of Common Stock
1/23/2018
The offering is expected to close on or about January 25, 2018, subject to customary closing conditions.
-
Histogenics Corporation Announces Receipt of $10M Up-front Payment for Japanese Neocart Agreement
1/9/2018
Histogenics and MEDINET announced entering into the agreement in December 2017.
-
Histogenics, MEDINET Ink Pact for Development and Commercialization of NeoCart for the Japanese M...
12/21/2017
Transaction Terms Include a $10M Up-front Payment with a Potential of $87m in Total Milestones, and Tiered Royalties on Sales -
Histogenics Corporation Announces Third Quarter 2017 Financial and Operating Results
11/9/2017
Loss from operations was $(5.7) million in the third quarter of 2017, compared to $(6.6) million in the third quarter of 2016.
-
Histogenics Corporation to Report Third Quarter 2017 Financial Results on November 9, 2017
10/26/2017
The Company will host a conference call and webcast at 8:30 a.m. ET to review financial and operational results for the quarter ended September 30, 2017 and provide a company update.
-
Histogenics Promotes Stephen Kennedy To Executive Vice President & Chief Operating Officer
10/13/2017
-
Histogenics Promotes Stephen Kennedy To Executive Vice President & Chief Operating Officer
10/12/2017
-
Histogenics Announces Publication Of Additional Biomechanical Data From Human Engineered Cartilage Testing
10/3/2017
-
Histogenics Announces Second Quarter 2017 Financial And Operating Results
8/10/2017
-
Histogenics To Announce Second Quarter 2017 Financial Results On August 10, 2017
7/27/2017
-
Massachusetts’ Histogenics Looks to NeoCart for Replacing Knee Cartilage Loss
7/25/2017
-
Histogenics Announces Publication Of Data From Collagen And Chondrocyte 3-D Bioprinting Study
7/11/2017